Electronic signatures and approval chains in practice

FDA 21 CFR Part 11 defines when electronic signatures are trustworthy. This guide is the operational half: how approval chains and e-signatures should behave inside requirements, tests, risk, and releases — without turning every edit into a signing ceremony.

What the workflow has to do

For regulated transitions (approve requirement baseline, sign a test run, accept residual risk, release a bundle), a defensible system typically needs:

1. Controlled states — not every field edit is a signature event; defined transitions are.
2. Approval rules — who must sign (role, group, or named chain), in what order, with what quorum.
3. Signature meaning — the signer attests to a specific meaning (review complete, approved for use, etc.), recorded with the signature.
4. Re-authentication — the signer proves they are present (password / SSO step-up), not that someone left a session open.
5. Unique binding — signature tied to the person and the exact record version; not a pasted image.
6. Audit trail — who, what, when, and previous values remain readable for as long as the record is retained.

Product-side, that is the shape of Approvals when compliance controls are enabled.

Optional until you need it

Not every team — and not every project inside a team — needs Part 11 on day one. The useful product property is: signatures and chains are workflow settings, not a permanent mode that slows non-regulated work. Turn them on for the projects and item types that require them; leave them off elsewhere. Buyers should ask vendors to demonstrate both modes, not only the marketing screenshot of a signature dialog.

Approval chains vs ad-hoc review

Mechanism	Good for	Weak for
Informal comments / review sessions	Early design collaboration	Predicate-rule approvals that need attributable signatures
Single approver click	Low-risk transitions	Segregation of duties, multi-discipline release
Ordered approval chain	Design control, release, residual risk	Overkill for draft typo fixes

Use reviews for collaboration; use signed chains for the moments your QMS calls “approve” or “release.”

Practical rollout tips

1. Start with one item type and one transition (e.g. requirement → Approved).
2. Document signature meanings in SOPs to match what the system records.
3. Train signers on re-authentication — shared passwords destroy the model.
4. Exercise the path in validation (see Validating an ALM for GxP).
5. Confirm you can export signed history for inspection.

Evaluation questions

1. Show a multi-step chain with re-authentication and recorded signature meaning.
2. Can signatures be required on some projects and off on others?
3. Is the audit trail independent and tamper-evident for signature events?
4. What happens to in-flight approvals if the item changes mid-chain?

Related reading

• FDA 21 CFR Part 11 guide
• Approvals module
• Validating an ALM for GxP
• Design controls evidence package